Ben is building the Oncology Franchise in the UK, having rejoined MSD in April 2014. Ben leads a cross-functional team with focus on accelerating the introduction and uptake of new, breakthrough oncology immunotherapy in the UK. Working with policy makers, and senior stakeholders at MHRA, NHS and NICE, the team were recently successful in providing access to cancer patients delivering the first medicine under the Early Access to Medicine Scheme (EAMS). Under Ben’s leadership the oncology team is committed to working collaboratively with the system to bring about the widespread adoption of new treatments that offer significant benefits to patients. Ben started his career working with elite athletes as an exercise physiologist at the Institute of Sport, Newcastle. He joined MSD in 1999 in his first role in pharmaceuticals and progressed through sales and marketing roles, before moving to Roche. He developed his experiences and expertise working in the Global organization in Basel, Switzerland before returning to lead the UK HER2 Breast Cancer Franchise and latterly the Anti-Angiogensis Franchise, overseeing the introduction of new formulations, expansion into new indications and the launch of multiple new molecular entities (NMEs). Ben is married, with five daughters and has lived in Sussex, Northumberland and North Yorkshire before settling in rural Hertfordshire. His interests (aside from parenting) include Rugby, Cycling, Golf, most spectator sports and country walks.